Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kalos

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Blood Cells, Molecules & Diseases|June 30, 2004
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignanciesLaurence J N Cooper, Zaid Al-Kadhimi, David DiGiusto, et al.
Human Gene Therapy|August 16, 2011
Treatment of advanced leukemia in mice with mRNA engineered T cellsDavid M Barrett, Yangbing Zhao, Xiaojun Liu, et al.
The Prostate|June 4, 2004
Prostein expression is highly restricted to normal and malignant prostate tissuesMichael Kalos, Jon Askaa, Bonnie L Hylander, et al.
Cancer Immunology Research|April 30, 2014
T cells expressing chimeric antigen receptors can cause anaphylaxis in humansMarcela V Maus, Andrew R Haas, Gregory L Beatty, et al.
Science Translational Medicine|November 11, 2011
Harmonization of immune biomarker assays for clinical studiesSjoerd H van der Burg, Michael Kalos, Cécile Gouttefangeas, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCedrik Michael Britten, Sylvia Janetzki, Leah Ben-Porat, et al.
Journal of Translational Medicine|July 13, 2011
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocolsSebastian Attig, Leah Price, Sylvia Janetzki, et al.
Immunity|October 17, 2009
"MIATA"-minimal information about T cell assaysSylvia Janetzki, Cedrik M Britten, Michael Kalos, et al.
Breast Cancer Research and Treatment|March 16, 2012
Mesothelin, a novel immunotherapy target for triple negative breast cancerJulia Tchou, Liang-Chuan Wang, Ben Selven, et al.
Blood|March 6, 2014
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cellsSaar Gill, Sarah K Tasian, Marco Ruella, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Blood Cells, Molecules & Diseases|June 30, 2004
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignanciesLaurence J N Cooper, Zaid Al-Kadhimi, David DiGiusto, et al.
Human Gene Therapy|August 16, 2011
Treatment of advanced leukemia in mice with mRNA engineered T cellsDavid M Barrett, Yangbing Zhao, Xiaojun Liu, et al.
The Prostate|June 4, 2004
Prostein expression is highly restricted to normal and malignant prostate tissuesMichael Kalos, Jon Askaa, Bonnie L Hylander, et al.
Cancer Immunology Research|April 30, 2014
T cells expressing chimeric antigen receptors can cause anaphylaxis in humansMarcela V Maus, Andrew R Haas, Gregory L Beatty, et al.
Science Translational Medicine|November 11, 2011
Harmonization of immune biomarker assays for clinical studiesSjoerd H van der Burg, Michael Kalos, Cécile Gouttefangeas, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCedrik Michael Britten, Sylvia Janetzki, Leah Ben-Porat, et al.
Journal of Translational Medicine|July 13, 2011
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocolsSebastian Attig, Leah Price, Sylvia Janetzki, et al.
Immunity|October 17, 2009
"MIATA"-minimal information about T cell assaysSylvia Janetzki, Cedrik M Britten, Michael Kalos, et al.
Breast Cancer Research and Treatment|March 16, 2012
Mesothelin, a novel immunotherapy target for triple negative breast cancerJulia Tchou, Liang-Chuan Wang, Ben Selven, et al.
Blood|March 6, 2014
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cellsSaar Gill, Sarah K Tasian, Marco Ruella, et al.
Pageof 8